INFLUENCE OF TYPE 2 SODIUM-GLUCOSE CO-TRANSPORTER INHIBITORS (DAPAGLIFLOZIN) ON THE INDICATORS OF TOTAL MORTALITY IN PATIENTS WITH TYPE 2 DIABETES (CARDIA-MOS STUDY, MOSCOW)

BACKGROUND: Widespread clinical use of drugs with cardioprotective/nephroprotective properties – particularly sodium-glucose cotransporter type 2 inhibitors (SGLT2i) – is based on results of large-scale international randomised trials. Meanwhile, there are no data demonstrating a potential effect of these drugs on mortality rates in real clinical practice in Russian patients. To address this lacuna, CARDIA-MOS study was conducted on a population of patients with type 2 diabetes (T2D) in Moscow.

OBJECTIVE: To study the effect of SGLT2i on total mortality in T2D patients in Moscow.

MATERIALS AND METHODS: To evaluate the frequency of different outcomes, two samples of patients were selected according to predetermined criteria: 1) patients who started SGLT2i (dapagliflozin) therapy in 2017; 2) a control group (no SGLT2i administration) matching the dapagliflozin group in terms of key indicators: age, T2D duration, cardiovascular diseases, insulin therapy, HbA1c level.

RESULTS: At Phase 1, data of 499 patients who started dapagliflozin treatment in 2017 were analysed against those of the 499 control group patients (n=998). The groups’ baseline characteristics were generally comparable. Pre-study SBP and HbA1c were worse in the dapagliflozin group. The use of dapagliflozin was associated with a 39% reduction in the relative risk of death from all causes (RR 0.614, 95% CI 0.417–0.903, p=0.013), led to a decrease in HbA1c levels by 0.8% (from 8.5 to 7.7%, p<0.001) over the 48-month-long observation.

CONCLUSION: The use of dapagliflozin in the treatment of T2D patients can reduce overall mortality and improve glycaemic control.

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157(4):107843. doi: https://doi.org/10.1016/j.diabres.2019.107843

2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi: https://doi.org/10.1038/nrendo.2017.151

3. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi: https://doi.org/10.2337/dci18-0033

4. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493. doi: https://doi.org/10.2337/dci19-0066

5. Российская ассоциация эндокринологов. Клинические рекомендации. Сахарный диабет 2 типа у взрослых. М.: Минздрав РФ; 2021. [Russian Association of Endocrinologists. Clinical guidelines. Type 2 Diabetes Mellitus in Adults. Moscow: Minzdrav RF; 2021. (In Russ.)].

6. Калашников В.Ю., Викулова О.К., Железнякова А.В., и др. Эпидемиология сердечно-сосудистых заболеваний у больных сахарным диабетом, по данным федерального регистра Российской Федерации (2013–2016 гг.). Сахарный диабет. 2019;22(2):105-114. [Kalashnikov VY, Vikulova OK, Zheleznyakova AV, et al. Epidemiology of cardiovascular diseases among patients with diabetes mellitus according to the federal diabetes register of the Russian Federation (2013–2016). Diabetes mellitus. 2019;22(2):105-114. (In Russ.)]. doi: https://doi.org/10.14341/DM10167

7. Pecoits-Filho R, Abensur H, Betônico CCR, et al. Interactions between kidney disease and diabetes: dangerous liaisons. Diabetol Metab Syndr. 2016;8(1):50. doi: https://doi.org/10.1186/s13098-016-0159-z

8. Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. Eur Heart J. 2018;39(5):363-370. doi: https://doi.org/10.1093/eurheartj/ehx511

9. Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. Diabetologia. 2019;62(3):357-369. doi: https://doi.org/10.1007/s00125-018-4801-1

10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657. doi: https://doi.org/10.1056/NEJMoa1611925

11. Usman MS, Siddiqi TJ, Memon MM, et al. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(5):495-502. doi: https://doi.org/10.1177/2047487318755531

12. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39. doi: https://doi.org/10.1016/S0140-6736(18)32590-X

13. Forxiga 10 mg film-coated tablets — Summary of Product Characteristics (SmPC) [Internet]. Available from: https://www.medicines.org.uk/emc/product/7607/smpc [cited April 18, 2022].

14. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an sglt2 inhibitor, on hba1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473-1478. doi: https://doi.org/10.2337/dc11-1693

15. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357. doi: https://doi.org/10.1056/NEJMoa1812389

16. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11(1):43. doi: https://doi.org/10.1186/1741-7015-11-43

17. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes, Obes Metab. 2011;13(10):928-938. doi: https://doi.org/10.1111/j.1463-1326.2011.01434.x

18. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288-2296. doi: https://doi.org/10.1093/eurheartj/ehv239

19. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-2125. doi: https://doi.org/10.1007/s00125-018-4663-6

20. Wilding J, Bailey C, Rigney U, et al. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes. 2017;11(5):437-444. doi: https://doi.org/10.1016/j.pcd.2017.04.004

21. Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: A retrospective cohort analysis. Diabetes Technol Ther. 2017;19(11):685-691. doi: https://doi.org/10.1089/dia.2017.0134

22. Han E, Kim A, Lee SJ, et al. Characteristics of dapagliflozin responders: A longitudinal, prospective, nationwide dapagliflozin surveillance study in Korea. Diabetes Ther. 2018;9(4):1689-1701. doi: https://doi.org/10.1007/s13300-018-0470-9

23. Fadini GP, Zatti G, Baldi I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes, Obes Metab. 2018;20(7):1781-1786. doi: https://doi.org/10.1111/dom.13280

24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: https://doi.org/10.1056/NEJMoa1504720

25. Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observationa. Diabetes, Obes Metab. 2018;20(2):344-351. doi: https://doi.org/10.1111/dom.13077

26. Bajaj HS, Raz I, Mosenzon O, et al. Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial. Diabetes, Obes Metab. 2020;22(7):1122-1131. doi: https://doi.org/10.1111/dom.14011

27. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606-617. doi: https://doi.org/10.1016/S2213-8587(19)30180-9